IP Library Granted Patent US 7,820,618
Granted Patent B2
US 7,820,618 · App. 11/867,433 · Granted Oct 26, 2010

Energy status of an individual by enhanced usage of an endogenous fuel source

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,820,618
App. No.
11/867,433
Granted
Oct 26, 2010
Kind
B2
Abstract

The present invention relates to a method of improving the energy status of an individual by enhancing the usage of lactate. Improved lactate usage is accomplished through a composition comprising lactate precursors, adrenergic receptor agonists and insulinotropic agents.

Claims (22)

1. A composition for improving the usage of lactate for energy in a mammal comprising; one or more adrenergic receptor agonists; one or more lactate precursors; and one or more insulinotropic agents.

2. The composition of claim 1 wherein; the adrenergic receptor agonist is caffeine in an amount from about 5 mg to about 500 mg.

3. The composition of claim 2 wherein; the lactate precursor is selected from the group consisting of: glutamine, and pyruvate; and wherein the insulinotropic agent is selected from the group consisting of: leucine, arginine, methyl pyruvate, and methyl succinate.

4. The composition of claim 2 wherein; the lactate precursor is glutamine; and the insulinotropic agent is leucine.

5. The composition of claim 4 wherein; the amount of glutamine is from about 0.05 g to about 5.00 g; and the amount of leucine or derivative of leucine is from about 10 mg to about 7.50 g.

6. The composition of claim 2 wherein; the lactate precursor is glutamine; and the insulinotropic agent is arginine.

7. The composition of claim 6 wherein; the amount of glutamine is from about 0.05 g to about 5.00 g; and the amount of arginine is from about 50 mg to about 5.00 g.

8. The composition of claim 2 wherein; the lactate precursor is pyruvate; and the insulinotropic agent is leucine.

9. The composition of claim 8 wherein; the amount of pyruvate is from about 1 mg to about 1000 mg; and the amount of leucine is from about 10 mg to about 7.50 g.

10. The composition of claim 2 wherein; the lactate precursor is pyruvate; and the insulinotropic agent is arginine.

11. The composition of claim 10 wherein; the amount of pyruvate is from about 1 mg to about 1000 mg; and the amount of arginine is from about 50 mg to about 5.00 g.

12. A method of improving the usage of lactate for energy in a mammal comprising the step of administering to the mammal a composition comprising; one or more adrenergic receptor agonist; one or more lactate precursors; and one or more insulinotropic agents.

13. The method of claim 12 wherein; the adrenergic receptor agonist is caffeine in an amount from about 5 mg to about 500 mg.

14. The method of claim 13 wherein; the lactate precursor is selected from the group consisting of: glutamine, and pyruvate; and the insulinotropic agent is selected from the group consisting of: leucine, arginine, methyl pyruvate, and methyl succinate.

15. The method of claim 12 wherein; the lactate precursor is glutamine; and the insulinotropic agent is leucine.

16. The method of claim 15 wherein; the amount of glutamine is from about 0.05 g to about 5.00 g; and the amount of leucine is from about 10 mg to about 7.50 g.

17. The method of claim 12 wherein; the lactate precursor is glutamine; and the insulinotropic agent is arginine.

18. The method of claim 17 wherein; the amount of glutamine is from about 0.05 g to about 5.00 g; and the amount of arginine is from about 50 mg to about 5.00 g.

19. The method of claim 12 wherein; the lactate precursor is pyruvate; and the insulinotropic agent is leucine.

20. The method of claim 19 wherein; the amount of pyruvate is from about 1 mg to about 1000 mg; and the amount of leucine is from about 10 mg to about 7.50 g.

21. The method of claim 12 wherein; the lactate precursor is pyruvate; and the insulinotropic agent is arginine.

22. The method of claim 21 wherein; the amount of pyruvate is from about 1 mg to about 1000 mg; and the amount of arginine is from about 50 mg to about 5.00 g.

Assignments (14)
RELEASE OF SECURITY INTEREST Recorded May 29, 2026
From: ROYAL BANK OF CANADA
To: NORTHERN INNOVATIONS HOLDING CORP.
Reel/Frame 075647/0267 →
SECURITY AGREEMENT Recorded May 28, 2026
From: LOVATE HEALTH SCIENCES INTERNATIONAL INC.; NORTHERN INNOVATIONS HOLDING CORP.; LOVATE HEATH SCIENCES U.S.A. INC.
To: FGI WORLDWIDE LLC
Reel/Frame 075641/0893 →
MERGER AND CHANGE OF NAME Recorded Sep 30, 2024
From: ROYAL BANK OF CANADA; HSBC TRUST COMPANY (CANADA); HSBC MORTGAGE CORPORATION (CANADA); HSBC FINANCE MORTGAGES INC.; HSBC BANK CANADA + 4 OTHERS NOTED ABOVE IN 'CONVEYING PARTY DATA'
To: ROYAL BANK OF CANADA/BANQUE ROYALE DU CANADA
Reel/Frame 069072/0683 →
CORRECTIVE ASSIGNMENT TO CORRECT THE SERIAL NUMBER OF PATENT NUMBER 7,645,812 TO 7,465,812 PREVIOUSLY RECORDED AT REEL: 059662 FRAME: 0958. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Apr 26, 2022
From: NORTHERN INNOVATIONS HOLDING CORP.
To: HSBC BANK CANADA
Reel/Frame 059793/0777 →
SECURITY INTEREST Recorded Apr 21, 2022
From: NORTHERN INNOVATIONS HOLDING CORP.
To: HSBC BANK CANADA
Reel/Frame 059662/0958 →
SECURITY INTEREST Recorded Dec 23, 2016
From: NORTHERN INNOVATIONS HOLDING CORP.
To: HSBC BANK CANADA
Reel/Frame 040758/0014 →
CHANGE OF NAME Recorded Jun 21, 2016
From: 2508304 ONTARIO LIMIITED
To: NORTHERN INNOVATIONS HOLDING CORP
Reel/Frame 039095/0992 →
MERGER Recorded Jun 21, 2016
From: OLD NORTHERN INNOVATIONS CORP; NORTHERN INNOVATIONS HOLDING CORP
To: OLD NORTHERN INNOVATIONS CORP
Reel/Frame 038967/0249 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2016
From: OLD NORTHERN INNOVATIONS CORP
To: 2462096 ONTARIO LIMITED
Reel/Frame 038966/0836 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2016
From: OLD NORTHERN INNOVATIONS CORP
To: 2508304 ONTARIO LIMIITED
Reel/Frame 038967/0447 →
CHANGE OF NAME Recorded Jun 21, 2016
From: NORTHERN INNOVATIONS HOLDING CORP
To: OLD NORTHERN INNOVATIONS CORP
Reel/Frame 039094/0255 →
MERGER Recorded Jun 21, 2016
From: NORTHERN INNOVATIONS AND FORMULATIONS CORP
To: NORTHERN INNOVATIONS HOLDING CORP
Reel/Frame 039094/0312 →
CHANGE OF NAME Recorded Jun 21, 2016
From: 2462096 ONTARIO LIMITED
To: NORTHERN INNOVATIONS HOLDING CORP
Reel/Frame 039094/0433 →
MERGER Recorded Sep 5, 2011
From: MULTI FORMULATIONS LTD
To: NORTHERN INNOVATIONS AND FORMULATIONS CORP
Reel/Frame 026855/0956 →